Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet.

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet."— Presentation transcript:

1 Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet B  Deep Joshipura, MD, Abdulaziz Alomran, MD, Pedro Zancanaro, MD, David Rosmarin, MD  Journal of the American Academy of Dermatology  Volume 78, Issue 6, Pages e1 (June 2018) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Mean percent improvement of VASI score for total, facial, acral, truncal, and nonacral extremities from baseline to week 52 for all enrolled patients with vitiligo (n = 8). Data from their last recorded visit were used for patients (n = 3) who dropped out of the study. Phototherapy was permitted after week 20 (bold black arrow). VASI, Vitiligo Area Scoring Index. Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Repigmentation noted on truncal and nonacral extremities after twice-daily topical ruxolitinib application at baseline, week 20 (without phototherapy), and week 52 (with phototherapy) in 2 vitiligo patients after combination narrow band ultraviolet B. Journal of the American Academy of Dermatology  , e1DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet."

Similar presentations

Treatment of generalized lichen nitidus with narrowband ultraviolet B Jae-Hong Park, MD, Yun-Lim Choi, MD, Won-Serk Kim, MD, Dong-Youn Lee, MD, Jun-Mo.

Treatment of generalized lichen nitidus with narrowband ultraviolet B Jae-Hong Park, MD, Yun-Lim Choi, MD, Won-Serk Kim, MD, Dong-Youn Lee, MD, Jun-Mo.
Use of the diagonal mattress suture to prevent dog-ear formation

Use of the diagonal mattress suture to prevent dog-ear formation
Surgical margins for melanoma in situ

Surgical margins for melanoma in situ
Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.
Clavi syphilitici–an unusual presentation of syphilis

Clavi syphilitici–an unusual presentation of syphilis
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
A girl with a solitary red bulla

A girl with a solitary red bulla
Mary E. Logue, BA, Barrett J. Zlotoff, MD 

Mary E. Logue, BA, Barrett J. Zlotoff, MD 
Facial adenocarcinoma treated with intra-arterial chemotherapy

Facial adenocarcinoma treated with intra-arterial chemotherapy
Striking leflunomide efficacy against refractory cutaneous sarcoidosis

Striking leflunomide efficacy against refractory cutaneous sarcoidosis
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya.

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo  Stefan G. Vanderweil, MD, Shinya.

Similar presentations

Ads by Google